EU research results


English EN
Hyaluronic-Cisplatin Film for Implant in Malignant Mesothelioma Recurrence

Hyaluronic-Cisplatin Film for Implant in Malignant Mesothelioma Recurrence


Hyalcis is a novel medicinal product, based on an innovative biodegradable film technology, for the prevention of the recurrence after surgery of malignant pleural mesothelioma. The proposing company, PlumeStars s.r.l., has successfully applied to the European Medical Agency, obtaining in 2016 the orphan designation for Hyalcis. This entitles PlumeStars as unique provider of the product, i.e, a polymeric film to treat pleura mesothelioma, for which there are no satisfactory curative methods. To capture this unique business opportunity, the Phase 1 project will develop a detailed Business Plan achievable within 6 months, including technical feasibility assessment based on qualified feedback and requirements from users, detailed market analysis, competitors analysis, industrialization planning, key partnerships preparation, knowledge protection and financial planning. Mesothelioma is a very aggressive form of cancer linked to asbestos use in construction and industry. It is difficult to diagnose, highly resistant to treatment and full recovery is extremely rare. Over 43,000 people die every year worldwide for the disease and that 10,000 new cases of mesothelioma combined in Europe, North America, Japan and Australia occur each year. The solution developed by PlumeStars is a hydrophilic, thin and flexible film, sufficiently resistant to be applied intrapleural or in other districts, adhering to the mesothelial or epithelial surfaces. The cisplatin release from the film is prolonged providing high local concentrations of anticancer drug, precisely in situ where the residual tumor could develop. This introduces significant benefits in terms of effectiveness, limiting tumor recurrence, low toxicity and increased safety and efficiency. This benefits have been confirmed in the tests already carried out on animals. PlumeStars aims at reaching 25% of the 200M€/year target market in 5 years, including 2 years for industrialization and registration.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries




Strada Inzani 1
43124 Parma Pr


Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

EU Contribution

€ 50 000

Project information

Grant agreement ID: 867540


Ongoing project

  • Start date

    1 May 2019

  • End date

    31 October 2019

Funded under:




  • Overall budget:

    € 71 429

  • EU contribution

    € 50 000

Coordinated by: